Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

• Published in: Therapeutic Advances in Medical Oncology 2014-05, Vol.6 (3), p.101-114
• Main Authors: D’Antonio, Chiara, Passaro, Antonio, Gori, Bruno, Del Signore, Ester, Migliorino, Maria Rita, Ricciardi, Serena, Fulvi, Alberto, de Marinis, Filippo
• Format: Article
• Language: English
• Subjects: Brain cancer; Cancer therapies; Chemotherapy; Epidermal growth factor; Epidermal growth factor receptors; Gefitinib; Localization; Lung cancer; Lung diseases; Medical prognosis; Metastases; Metastasis; Monoclonal antibodies; Osteoclasts; Protein-tyrosine kinase; Radiation therapy; Reviews; Survival; Targeted cancer therapy; Zoledronic acid
• ISSN: 1758-8340; 1758-8359; 1758-8359
• DOI: 10.1177/1758834014521110

Bone and brain metastases are a very common secondary localization of disease in patients with lung cancer. The prognosis of these patients is still poor with a median survival of less than 1 year. Current therapeutic approaches include palliative radiotherapy and systemic therapy with chemotherapy and targeted agents. For bone metastasis, zoledronic acid is the most commonly used bisphosphonate to prevent, reduce the incidence and delay the onset of skeletal-related events (SREs). Recently, denosumab, a fully human monoclonal antibody directed against the receptor activator of nuclear factor κB (RANK) ligand inhibiting the maturation of pre-osteoclasts into osteoclasts, showed increased time to SREs and overall survival compared with zoledronic acid. The treatment of brain metastasis is still controversial. Available standard therapeutic options, such as whole brain radiation therapy and systemic chemotherapy, provide a slight improvement in local control, overall survival and symptom relief. More recently, novel target agents such as the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and afatinib have shown activity in patients with brain metastasis. Inter alia, in patients harboring EGFR mutations, the administration of EGFR TKIs is followed by a response rate of 70–80%, and a longer progression-free and overall survival than those obtained with standard chemotherapeutic regimens. This review is focused on the evidence for therapeutic strategies in bone and brain metastases due to lung cancer.